Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell lines.
about
aCGH local copy number aberrations associated with overall copy number genomic instability in colorectal cancer: coordinate involvement of the regions including BCR and ABL.Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance.Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells.
P2860
Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell lines.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Imatinib mesylate (STI571) pre ...... l in hematopoietic cell lines.
@en
type
label
Imatinib mesylate (STI571) pre ...... l in hematopoietic cell lines.
@en
prefLabel
Imatinib mesylate (STI571) pre ...... l in hematopoietic cell lines.
@en
P2093
P50
P1433
P1476
Imatinib mesylate (STI571) pre ...... l in hematopoietic cell lines.
@en
P2093
Alexandra Moehring
Cornelius Miething
Heiko van der Kuip
Justus Duyster
Walter E Aulitzky
P304
P356
10.1016/J.LEUKRES.2003.08.012
P577
2004-04-01T00:00:00Z